Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Galapagos NV
Galapagos NV
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Drug Delivery
Galapagos and NovAliX enter integrated drug discovery collaboration
The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development
Galapagos expands fibrosis portfolio
Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development
Pharnext announces R&D agreement with Galapagos
The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
Research & Development
Galapagos ends inflammation partnership with Janssen
Long-running alliance started in 2007
Research & Development
AbbVie and Galapagos to co-develop cystic fibrosis therapies
Firms aim to start Phase 1 trials at end of 2014
Research & Development
Galapagos appoints CEO of Service Division
David Smith returns to the Belgian firm in new role
Research & Development
Galapagos receives €2.5m grant for IBD research
IWT-funded project aims to identify new compounds for future treatment of IBD
Subscribe now